This database contains 13 studies, archived under the term: "data interpretation statistical"
Click here to filter this large number of results.
The effects of ramipril in individuals at risk for Alzheimer’s disease: results of a pilot clinical trial
Wharton, Whitney,
Stein, James H.,
Korcarz, Claudia,
Sachs, Jane,
Olson, Sandra R.,
Zetterberg, Henrik,
Dowling, Maritza,
Ye, Shuyun,
Gleason, Carey E.,
Underbakke, Gail,
Jacobson, Laura E.,
Johnson, Sterling C.,
Sager, Mark A.,
Asthana, Sanjay,
Carlsson, Cynthia M.
Research shows that certain antihypertensives taken during midlife confer Alzheimer’s disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-β (Aβ) levels and ACE activity, arterial function, and cognition in participants with […]
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease
We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington’s disease, with additional evaluation of its safety and tolerability. This was a randomized, double-blind, placebo-controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty-seven subjects enrolled from […]
Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer’s disease
Fehlbaum-Beurdeley, Pascale,
Sol, Olivier,
Désiré, Laurent,
Touchon, Jacques,
Dantoine, Thierry,
Vercelletto, Martine,
Gabelle, Audrey,
Jarrige, Anne-Charlotte,
Haddad, Raphaël,
Lemarié, Jean Christophe,
Zhou, Weiyin,
Hampel, Harald,
Einstein, Richard,
Vellas, Bruno
Biomarkers have gained an increased importance in the past years in helping physicians to diagnose Alzheimer’s disease (AD). This study was designed to identify a blood-based, transcriptomic signature that can differentiate AD patients from control subjects. The performance of the signature was then evaluated for robustness in an independent blinded sample population. RNA was extracted […]
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease
Burns, Alistair,
Perry, Elaine,
Holmes, Clive,
Francis, Paul,
Morris, Julie,
Howes, Melanie-Jayne R.,
Chazot, Paul,
Lees, George,
Ballard, Clive
Background/aims: Behavioural and psychological symptoms (BPSD) are frequent in people with Alzheimer’s disease and cause considerable stress to patients and their carers. Antipsychotics have been widely used as a first-line treatment, resulting in an estimated 1,800 excess strokes and 1,600 excess deaths in the UK alone. Safe and effective alternatives are urgently needed. Based upon […]
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study
Coker, L. H.,
Hogan, P. E.,
Bryan, N. R.,
Kuller, L. H.,
Margolis, K. L.,
Bettermann, K.,
Wallace, R. B.,
Lao, Z.,
Freeman, R.,
Stefanick, M. L.,
Shumaker, S. A.
Objective: The Women’s Health Initiative Memory Study (WHIMS) hormone therapy (HT) trials reported that conjugated equine estrogen (CEE) with or without medroxyprogesterone acetate (MPA) increases risk for all-cause dementia and global cognitive decline. WHIMS MRI measured subclinical cerebrovascular disease as a possible mechanism to explain cognitive decline reported in WHIMS.; Methods: We contacted 2,345 women […]
Quality of life in nursing home residents with advanced dementia
Objectives: To examine quality of life (QOL) in nursing home (NH) residents with advanced dementia and identify correlates of QOL near the end of life.; Design: Cross-sectional data derived from NH records, interviews with residents’ surrogate decision-makers, QOL ratings by NH caregivers, and assessment of residents’ cognitive function.; Setting: Three NHs in Maryland.; Participants: A […]